tiprankstipranks
Trending News
More News >
HABA Laboratories, Inc. (JP:4925)
:4925
Japanese Market
Advertisement

HABA Laboratories, Inc. (4925) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4925

HABA Laboratories, Inc.

(4925)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
¥1,780.00
▲(5.70% Upside)
HABA Laboratories scores a 63, driven primarily by its strong valuation metrics, including a low P/E ratio and attractive dividend yield. While financial performance shows resilience in balance sheet strength, challenges in revenue growth and profitability weigh on the score. Technical analysis indicates mixed signals, with short-term bearish momentum but potential longer-term support.

HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)

HABA Laboratories, Inc. Business Overview & Revenue Model

Company DescriptionHABA Laboratories,Inc. manufactures and sells skin care, and hair and body care products in Japan and internationally. Its skin care products include cleansers/face washes, toners, special care products, and squalane oils; and hair and body care products comprise shampoos, conditioners, soaps, and hair and hand treatment products. The company sells its products through mail order, shops, drug/variety stores, and internet. It has approximately 70 HABA shops located in department stores, shopping malls, etc. HABA Laboratories,Inc. was founded in 1983 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHABA Laboratories, Inc. generates revenue primarily through the sale of its skincare and cosmetic products. The company's key revenue streams include direct sales through its retail stores and online platforms, as well as distribution through third-party retailers and partners. HABA Laboratories leverages its brand reputation for safety and quality to attract and retain a loyal customer base. The company also engages in marketing and promotional activities to expand its market reach and increase sales. Strategic partnerships with retailers and distributors help HABA Laboratories to extend its product availability and enhance its earnings potential.

HABA Laboratories, Inc. Financial Statement Overview

Summary
HABA Laboratories shows a mixed financial picture. The income statement is pressured by revenue declines and inconsistent profitability, while the balance sheet remains strong with low leverage and solid equity. Cash flow generation is improving, but historical volatility presents challenges. The company demonstrates resilience in its financial stability but needs to address profitability and growth concerns.
Income Statement
55
Neutral
HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.
Balance Sheet
70
Positive
The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.
Cash Flow
60
Neutral
Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.02B12.06B12.32B12.04B12.91B14.31B
Gross Profit8.08B7.99B8.03B8.17B8.79B10.20B
EBITDA826.86M811.56M-1.31B17.05M448.30M960.14M
Net Income638.78M576.57M-2.12B-707.87M-269.03M216.42M
Balance Sheet
Total Assets11.76B12.34B12.43B14.66B15.69B17.44B
Cash, Cash Equivalents and Short-Term Investments4.48B4.74B3.96B4.82B5.65B5.66B
Total Debt1.56B1.82B2.36B2.03B2.56B3.92B
Total Liabilities2.95B3.42B3.92B3.88B4.05B5.40B
Stockholders Equity8.82B8.93B8.51B10.77B11.64B12.04B
Cash Flow
Free Cash Flow0.001.48B-1.02B-232.69M1.53B-346.95M
Operating Cash Flow0.001.62B-587.92M55.96M1.71B534.71M
Investing Cash Flow0.00-147.18M-441.79M-214.40M-216.49M-925.08M
Financing Cash Flow0.00-689.49M171.06M-676.32M-1.51B825.38M

HABA Laboratories, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1684.00
Price Trends
50DMA
1715.30
Negative
100DMA
1705.22
Negative
200DMA
1692.92
Negative
Market Momentum
MACD
-3.72
Positive
RSI
32.55
Neutral
STOCH
1.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Negative. The current price of 1684 is below the 20-day moving average (MA) of 1747.10, below the 50-day MA of 1715.30, and below the 200-day MA of 1692.92, indicating a bearish trend. The MACD of -3.72 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 1.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
¥10.96B21.6934.71%6.00%27.84%51.43%
63
Neutral
¥6.38B9.962.36%-3.27%
63
Neutral
¥10.78B29.454.66%2.27%10.56%-52.16%
60
Neutral
¥6.16B161.220.97%1.56%-9.81%
52
Neutral
¥6.42B13.637.13%-20.62%
45
Neutral
¥5.14B20.421.67%7.21%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4925
HABA Laboratories, Inc.
1,684.00
-211.23
-11.15%
JP:4926
C'BON COSMETICS Co., Ltd.
1,209.00
-53.78
-4.26%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
767.00
-48.06
-5.90%
JP:4932
Almado, Inc.
1,084.00
118.01
12.22%
JP:4934
Premier Anti-Aging Co., Ltd.
736.00
-39.00
-5.03%
JP:4936
AXXZIA, Inc.
441.00
-192.05
-30.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 01, 2025